CSL (CSLLY) Free Cash Flow per Share: $1.16 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSLLY CSL Ltd CSLLY
67 GF Score
Price $30.60
GF Value $47.57
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CSL Free Cash Flow per Share?

CSL CSLLY +2.31% 67 Free Cash Flow per Share is $1.16 as of Jun. 2026. GuruFocus rates CSLLY with a GF Score™ of 67/100 and a GF Value™ of $47.57 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,105 Biotechnology companies, CSL ranks better than 68.51% on this metric.

CSL's Free Cash Flow per Share for the six months ended in Jun. 2026 was $0.83. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $1.16.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of CSL was -17.90% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 33.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the FCF Growth Rate using Free Cash Flow per Share data.

The historical rank and industry rank for CSL's Free Cash Flow per Share or its related term are showing as below:

CSLLY' s 3-Year FCF Growth Rate Range Over the Past 10 Years
Min: -38   Med: 13.7   Max: 315.8
Current: 33.1

During the past 13 years, CSL's highest 3-Year average Free Cash Flow per Share Growth Rate was 315.80% per year. The lowest was -38.00% per year. And the median was 13.70% per year.

CSLLY's 3-Year FCF Growth Rate is ranked better than
68.51% of 1105 companies
in the Biotechnology industry
Industry Median: 19.3 vs CSLLY: 33.10

CSL  (OTCPK:CSLLY) Free Cash Flow per Share Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is because research shows that five years is the length of the typical business cycle.

Therefore, as of Jun26, CSL's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Jun26)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0.82916667/20.06+0.0841
=12.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


CSL Free Cash Flow per Share Related Terms


CSL Free Cash Flow per Share Historical Data

* Premium members only.

The historical data trend for CSL's Free Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Free Cash Flow per Share Chart

CSL Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Free Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 0.47 0.78 1.31 1.16

CSL Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25 Jun26
Free Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.59 0.00 0.33 0.83

CSLLY vs VRTX, REGN, MRNA: Free Cash Flow per Share Comparison

For the Biotechnology subindustry, CSL's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL Price-to-Free-Cash-Flow vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CSL's Price-to-Free-Cash-Flow falls into.


CSLLY
67GF Score
CSL Ltd CSLLY
Free Cash Flow per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Free Cash Flow per Share Calculation

Free Cashflow per Share is the amount of Free Cashflow per outstanding share of the company's stock.

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Note: GuruFocus does not calculate Free Cash Flow Per Share when Capital Expenditure is 0.

CSL's Free Cash Flow Per Share for the fiscal year that ended in Jun. 2026 is calculated as

Free Cash Flow Per Share(A: Jun. 2026 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(3512+-1280)/1927.921
=2232/1927.921
=1.16

CSL's Free Cash Flow Per Share for the quarter that ended in Jun. 2026 is calculated as

Free Cash Flow Per Share(Q: Jun. 2026 )
=(Cash Flow from Operations+Capital Expenditure)/Shares Outstanding (Diluted Average)
=(2210+-624)/1921.540
=1586/1921.540
=0.83

Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Free Cash Flow per Share of $1.16 mean?
CSL (CSLLY) has a Free Cash Flow per Share of $1.16 as of Jun. 2026. Free cash flow per share represents the pre-share value of cash following operating and capital expenditures. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #348 out of 1105 companies in the Biotechnology industry, placing it in the top 31.5%.
Is CSL's Free Cash Flow per Share too high?
CSL's current Free Cash Flow per Share is $1.16. The Biotechnology industry median Free Cash Flow per Share is 19.30. CSL's value of $1.16 is 94% below this industry median. Based on the distribution chart, CSL ranks #348 out of 1105 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Free Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #348 out of 1105 companies for Free Cash Flow per Share. This puts CSL in the upper half of its industry. The industry median Free Cash Flow per Share is 19.30. CSL's value of $1.16 is 94% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Free Cash Flow per Share for a Biotechnology company?
The median Free Cash Flow per Share among Biotechnology companies is 19.30, based on 1,105 companies in the industry. Companies in the top quartile (top 25%) have a Free Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Free Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Free Cash Flow per Share of $1.16 is 94% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Free Cash Flow per Share mean?
A high Free Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Free cash flow per share represents the pre-share value of cash following operating and capital expenditures. View historical data on CSL and its competitors. For the Biotechnology industry, the median Free Cash Flow per Share is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Free Cash Flow per Share is $1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.57, compared to a current price of $30.60 — trading 35.7% below its estimated fair value. The current Free Cash Flow per Share is $1.16 and 94% below the Biotechnology industry median of 19.30. CSL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Free Cash Flow per Share calculated?
Free Cash Flow per Share is calculated from a company's financial statements. For CSL (CSLLY), the current Free Cash Flow per Share is $1.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $30.60 is trading 35.7% below its estimated GF Value™ of $47.57. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Free Cash Flow per Share: $1.16
  • GF Value™: $47.57 vs. price of $30.60 (35.7% below fair value)
  • GF Score™: 67/100 with 6 warning signs
  • Industry Position: 94% below the Biotechnology median (#348 of 1105)

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
67GF Score

Get the complete analysis for CSLLY

Free Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.60
Price
$47.57
GF Value